TY - JOUR
T1 - Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms
AU - Mughal, Tariq I.
AU - Abdel-Wahab, Omar
AU - Rampal, Raajit
AU - Mesa, Ruben
AU - Koschmieder, Steffen
AU - Levine, Ross
AU - Hehlmann, Rüdiger
AU - Saglio, Giuseppe
AU - Barbui, Tiziano
AU - Van Etten, Richard A.
N1 - Publisher Copyright:
© 2016 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2016/7/2
Y1 - 2016/7/2
N2 - This review is based on the deliberations at the 5th John Goldman Colloquium held in Estoril on 2nd October 2015 and the 9th post-ASH International Workshop on chronic myeloid leukemia (CML) and BCR-ABL1-negative myeloproliferative neoplasms (MPN) which took place on the 10th–11th December 2014, immediately following the 56th American Society of Hematology Annual Meeting. It has been updated since and summarizes the most recent advances in the biology and therapy of these diseases, in particular updates of genetics of MPN, novel insights from mouse MPN models, targeting CML stem cells and its niche; clinical advances include updates on JAK2 inhibitors and other therapeutic approaches to BCR-ABL1-negative MPNs, the use of alpha interferons, updates on tyrosine kinase inhibitors (TKI) randomized trials in CML, TKI cessation studies, and optimal monitoring strategies.
AB - This review is based on the deliberations at the 5th John Goldman Colloquium held in Estoril on 2nd October 2015 and the 9th post-ASH International Workshop on chronic myeloid leukemia (CML) and BCR-ABL1-negative myeloproliferative neoplasms (MPN) which took place on the 10th–11th December 2014, immediately following the 56th American Society of Hematology Annual Meeting. It has been updated since and summarizes the most recent advances in the biology and therapy of these diseases, in particular updates of genetics of MPN, novel insights from mouse MPN models, targeting CML stem cells and its niche; clinical advances include updates on JAK2 inhibitors and other therapeutic approaches to BCR-ABL1-negative MPNs, the use of alpha interferons, updates on tyrosine kinase inhibitors (TKI) randomized trials in CML, TKI cessation studies, and optimal monitoring strategies.
KW - Molecular genetics
KW - myeloid leukemias and dysplasias
KW - stem and primitive progenitor cells
UR - http://www.scopus.com/inward/record.url?scp=84975248782&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84975248782&partnerID=8YFLogxK
U2 - 10.1080/10428194.2016.1185783
DO - 10.1080/10428194.2016.1185783
M3 - Review article
C2 - 27240645
AN - SCOPUS:84975248782
SN - 1042-8194
VL - 57
SP - 1517
EP - 1526
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 7
ER -